Current Trials & Studies
The WACBD is staffed by several internationally recognized researchers and conducts numerous clinical and translational studies. Many of these studies are enabled and enhanced by a strong collaborative relationship with the Research Institute at Bloodworks Northwest and the University of Washington.
-
Community Counts
Community Counts is a public health monitoring program funded by CDC’s Division of Blood Disorders. The purpose of this project is to gather and share information about common health issues, medical complications, and causes of death that affect people with bleeding disorders cared for in U.S. Hemophilia Treatment Centers (HTCs).
-
ATHN Transcends
ATHN Transcends is a natural history cohort study focused on participants with congenital or acquired non-neoplastic blood disorders and connective tissue disorders with bleeding tendencies. ATHN Transcends provides clinical researchers with a uniform, secure, unbiased, and enduring method to collect long-term safety and efficacy data to increase knowledge in these important areas of research.
-
Effects of Emicizumab vs. Factor VIII Prophylaxis on Joint and Bone Health in Severe Hemophilia A
The investigators propose to study longitudinal joint and bone density changes in patients with severe Hemophilia A.
-
Von Willebrand Factor in Pregnancy (VIP) Study
In pregnant women with von Willebrand disease (VWD) who by the third trimester do not have von Willebrand factor (VWF) or factor VIII (FVIII) levels greater than 50-100% specific guidance is lacking for delivery planning in terms of how high of a VWF level should be achieved to reduce bleeding.
-
A Phase 3, Open-label Interventional Study of an Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein, Efanesoctocog Alfa (BIVV001), in Patients With Severe Hemophilia A
To evaluate the efficacy of BIVV001 as a prophylaxis treatment in prophylaxis treatment arm.
-
Phase 3, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of PF-07055480 in Adult Male Participants With Moderately Severe to Severe Hemophilia A
C3731003 is a pivotal Phase 3 Study to evaluate the clinical efficacy and safety of a single IV infusion of PF-07055480 / giroctocogene fitelparvovec (Recombinant AAV2/6 Human Factor VIII Gene Therapy) in adult male participants with moderately severe or severe hemophilia A
-
Phase III, open-label, single-dose, multi-center multinational trial investigating a serotype 5 adeno-associated viral vector containing the Padua variant of a codon-optimized human factor IX gene administered to adult subjects with severe or moderately severe hemophilia B
This is an open-label, single-dose, multi-center, multinational trial to demonstrate the efficacy of AMT-061 and to further describe its safety profile.
-
Emicizumab in Patients With Acquired Hemophilia A (AHAEmi)
This is a phase II multicenter open-label, single-arm prospective study to evaluate the efficacy of prophylactic emicizumab administered on a scheduled basis to prevent bleeds in patients with acquired hemophilia A (AHA).
-
Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B
Treatment with PF-06741086 is anticipated to demonstrate a clinically relevant advantage and/or a major contribution to patient care in comparison to current methods of treatment for hemophilia A or B because it works differently than factor replacement products and will work in the presence of inhibitors.
24-Hour Triage & Consultation
If this is a medical emergency, please dial 911. For urgent bleeding concerns outside of regular business hours, call: (206) 614-1200
[For non-emergency inquiries during business hours, please call (206) 614-1200]
